Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 62Gastrointestinal 55Genitourinary 47CNS 11Other hematologic neoplasm 8Head & Neck 8Breast 7Lymphoid 6Gynecologic 6Dermatologic 6Other 5Sarcoma 3Plasma cell 3Classical hematology 3Myeloid 2Other neoplasm 1

Conditions

Multiple Myeloma 927Lymphoma 112Recurrence 94Neoplasms, Plasma Cell 92Lymphoma, Non-Hodgkin 67Immunoglobulin Light-chain Amyloidosis 60Hematologic Neoplasms 60Neoplasms 54Smoldering Multiple Myeloma 51Leukemia, Myeloid, Acute 51Leukemia 51Myelodysplastic Syndromes 47Leukemia, Lymphocytic, Chronic, B-Cell 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Hodgkin Disease 37Leukemia, Plasma Cell 26Myeloproliferative Disorders 24Monoclonal Gammopathy of Undetermined Significance 23Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Breast Neoplasms 22Amyloidosis 22Primary Myelofibrosis 21Lymphoma, Follicular 21Waldenstrom Macroglobulinemia 20Ovarian Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, B-Cell 17Colorectal Neoplasms 16

Interventions

daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Disease × Plasma cell × 1 year × Clear all
NCT07075185 2026-04-24

inMMyCAR

Kelonia Therapeutics, Inc.

Phase 1 Recruiting
70 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

Peking University First Hospital

Phase 2/3 Not yet recruiting
300 enrolled
Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡